Available VP Level Opportunities

The firm is a research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging.

The entity is a privately held, clinical-stage biotechnology company that specializes in the discovery and development of next-generation antibody therapeutics designed to treat immune-mediated diseases, cancer, inflammatory disorders, and infectious diseases.

The organization is a commercial-stage medical technology company that develops and manufactures advanced surgical robotics for urology.

The organization is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics.

The firm is an established biotech dedicated to the pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer.

The organization is a public, clinical-stage biopharmaceutical company that specializes in developing trailblazing cell therapies.

The firm is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

The corporate entity is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults.

The firm is a clinical-stage biotechnology company based in South San Francisco, California that is focus ingon developing therapeutics that degrade disease-causing extracellular and membrane-bound proteins, rather than just inhibiting them.

The entity is a late-stage biotechnology company developing high-precision, allogeneic cell therapies designed to treat blood cancers, genetic blood disorders, and autoimmune diseases.

This clinical stage biotech based in the San Francisco Bay area aims to fundamentally change the way disease is treated using degrader-based medicines. Their journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.

The corp entity is a late-stage, newly public biopharmaceutical company specializing in sustained-release drug delivery systems for chronic ophthalmic diseases, primarily targeting glaucoma.

The corporation is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing transformative products in the areas of oncology, autoimmune disorders, infectious diseases and neurological disorders.

The corporate enterprise is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs.

The firm is a private, discovery-stage biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies to treat immunology and inflammation disease.

The company is an AI-driven biotechnology startup focused on decoding complex, historically overlooked neuroimmune and chronic conditions like Postural Orthostatic Tachycardia Syndrome (POTS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and Long COVID.

The firm is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation.

The corporate entity is a biotechnology company working to extend human health span by developing epigenetic reprogramming therapies.

The firm is an emerging biotechnology company developing next-generation in vivo CAR-T cell therapies and precision genomic medicines.

The firm is a biopharmaceutical company based in the San Francisco Bay Area specializing in antibody discovery and engineering, with platforms that span antibody-drug conjugates (ADCs), bispecifics, and multispecifics.

The firm is a commercial-stage biopharmaceutical company focused on developing and commercializing needle-free, patient-friendly treatments for severe allergic reactions.

This emerging start up organization is a San Diego-based biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies for people living with rare kidney and metabolic diseases.

Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, this start-up company is committed to solving oncology’s hardest problems. They have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.

The organization is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, they are creating novel products and development. strategies that overcome multi-drug resistance.

The organization is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies designed to overcome therapeutic resistance in cancer.

The enterprise is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye.

The organization is a clinical stage biotechnology company discovering and developing best-in-class antibodies to create life-changing therapies for patients, initially addressing unmet needs in hematology and immunology.

The firm is a biopharmaceutical company based in the San Francisco Bay Area specializing in antibody discovery and engineering, with platforms that span antibody-drug conjugates (ADCs), bispecifics, and multispecifics.

For over three decades, this highly successful commercial biotech has invented medicines that bring better futures to people with serious diseases. Currently, they have five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need.